SCHEMBL143889

SCHEMBL143889

Fc1ccc(C(F)(F)c2cc(Nc3nc4ccc(Br)cc4s3)nc(Cl)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 3/20 0.49
ITK Q08881 3/20 0.49
AURKB Q96GD4 1/20 0.49
MAPT P10636 9/20 0.41
NPC1 O15118 8/20 0.41
KDM4E B2RXH2 6/20 0.41
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
ALDH1A1 P00352 5/20 0.41
HTT P42858 2/20 0.41
MCL1 Q07820 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
RAB9A P51151 8/20 0.40
SMN1; SMN2 Q16637 7/20 0.40
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
DYRK1A Q13627 1/20 0.39
LMNA P02545 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL138887 0.86 RAB9A (0.52) LCKITKAURKBMAPTNPC1
SCHEMBL138176 0.85 LCK (0.55) LCKITKAURKBMAPTNPC1
SCHEMBL141486 0.85 LCK (0.67) LCKITKAURKBMAPTNPC1
SCHEMBL140313 0.83 LCK (0.55) LCKITKAURKBMAPTNPC1
SCHEMBL140481 0.79 ITK (0.78) LCKITKAURKBLRRK2
SCHEMBL140482 0.79 ITK (0.78) LCKITKAURKBLRRK2
SCHEMBL136247 0.77 LCK (0.67) LCKITKAURKBMAPTNPC1
SCHEMBL140467 0.75 DYRK1A (0.51) LCKITKAURKBDYRK1A
SCHEMBL808047 0.72 LCK (0.53) LCKMAPTNPC1KDM4EMEN1
SCHEMBL143888 0.71 LCK (0.41) LCKITKAURKBMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK LCK 189/4885ITK 2/4885AURKB 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.